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INTRODUCTION: Vitamin D deficiency is linked to poor treatment response in patients with Multiple S  clerosis. The 
aim of this study is to define the frequency of Vitamin D deficiency for early detection and timely intervention leading 
to improved morbidity rates.
OBJECTIVE: To determine the frequency of vitamin D deficiency in Multiple sclerosis patients present at neurology 
ward of a tertiary care hospital in Larkana
DURATION OF STUDY:  March 2016 to August 2016
STUDY DESIGN: Cross-sectional study  
Setting: Neurology Ward Chandka Medical College Hospital, Larkana
SUBJECTS: Ages of 18 and 60 years, either gender, diagnosis of MS for more than 3 months, sun exposure for at least 
30 minutes thrice per week for and give written informed consent were included in this study.  
METHODS:  This study was approved by an ethical review committee of the institute. Patients fulfilling inclusion criteria 
were enrolled in this study after taking written informed consent. The demographic variables like name, age, gender, 
duration of sun exposure & duration of disease were collected by the researcher. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this study were measured by radioimmunoassay. The data was 
analyzed using SPSS version 19. 
RESULTS: Mean age of enrolled participants was 43.6±11 years. Of 85 enrolled participants, 36 (42.4%) were male 
and 49 (57.6%) were female, the mean duration of disease was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried, 49 (57.6%) were employed, 43 (50.6%) were exposed to the sun for < 40 
minutes a day. The frequency of vitamin D deficiency among patients with multiple sclerosis was 17 (20%) cases. 
CONCLUSIONS: It is concluded from this study that the frequency of vitamin D deficiency among patients with multiple 
sclerosis was 20%.
KEYWORDS: Multiple sclerosis, vitamin D deficiency, sun exposure
O R I G I N A L  A R T I C L E
INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
(n=143)
Table 1: STRATIFIED ANALYSIS OF FREQUENCY OF 
VITAMIN D DEFICIENCY IN PATIENTS WITH 
MULTIPLE SCLEROSIS BY AGE
Table 2:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 




STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF 
DISEASE
Table 4:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF SUN EXPOSURE as 
Table 5:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY MARITAL STATUS
Table 6:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY EMPLOYMENT STATUS
DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
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Table 1: STRATIFIED ANALYSIS OF FREQUENCY OF 
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Table 5:
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SCLEROSIS BY MARITAL STATUS
Table 6:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY EMPLOYMENT STATUS
DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:
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DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
(n=143)
Table 1: STRATIFIED ANALYSIS OF FREQUENCY OF 
VITAMIN D DEFICIENCY IN PATIENTS WITH 
MULTIPLE SCLEROSIS BY AGE
Table 2:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 




STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF 
DISEASE
Table 4:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF SUN EXPOSURE as 
Table 5:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY MARITAL STATUS
Table 6:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY EMPLOYMENT STATUS
DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
(n=143)
Table 1: STRATIFIED ANALYSIS OF FREQUENCY OF 
VITAMIN D DEFICIENCY IN PATIENTS WITH 
MULTIPLE SCLEROSIS BY AGE
Table 2:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
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D DEFICIENCY IN PATIENTS WITH MULTIPLE 
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Table 4:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF SUN EXPOSURE as 
Table 5:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY MARITAL STATUS
Table 6:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY EMPLOYMENT STATUS
DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
(n=143)
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DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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INTRODUCTION: 
Multiple sclerosis (MS) is an autoimmune, 
inflammatory, neurodegenerative, 
T-lymphocyte-mediated disease of uncertain etiology. 
Mostly it is because of genetic susceptibility; 
epidemiologic studies suggest environmental influence 
because the development of MS correlates most 
strongly with rising latitude in both the northern and 
southern hemispheres1.
The diagnosis relies on recognition of the clinical 
patterns of the disease. Relapsing and remitting 
neurologic deficits is the hallmark of the disease in 
most patients. The pathologic hallmark of MS is focal 
demyelination within the brain and spinal cord. 
Although the lesions can occur at any site within the 
central nervous system, they have a predilection for 
involvement of the periventricular white matter, the 
corpus callosum, optic nerves, and the dorsal spinal 
cord. MS affects females two to three times more than 
male, risk increases from adolescence up to the age of 
35 and then gradually declines and is rare after the age 
of 65. MS is rare in equatorial climates, and its 
prevalence increases with distance from the equator. 
Higher latitudes result in lower ultraviolet radiation 
exposure and lower vitamin D levels2, from the relation 
with latitude; it appears that low solar UltraVoilet B 
(UVB) doses during winter are an important risk 
factor3.However, low UVB exposure in summer also 
plays a role. This is an observation that MS patients 
consistently have lower levels of vitamin D. one recent 
study has shown prevalence of vitamin D as 17% in 
patients with MS.4It is suggested that vitamin D may 
help to decrease the risk of MS and those patients with 
higher vitamin D levels are less likely to develop MS.5 
It is observed that higher vitamin D levels may help to 
reduce MS activity and a slower the rate of progression 
of MS.6 Higher vitamin D levels also helps to prevent 
disability in MS patients.7A case-control study 
compared the serum vitamin D levels of 103 MS 
patients with 110 controls and found that for every 
10-nmol/L increase in serum 25(OH)D level the odds of 
MS was reduced by 19% in women, suggesting a 
“protective” effect of higher vitamin D levels.8 In 
addition, a negative correlation was found between 
Expanded Disability Status Scale scores among female 
MS patients and 25(OH)D levels. There are several 
other studies have supported the finding that lower 
levels of vitamin D in MS patients are associated with 
more severe disability.9 Lower levels during relapses 
have also been reported in patients with 
relapse-remitting MS.10-12One small safety study of 
12 patients taking 1000 µg per day (40,000 IU) of 
vitamin D for 28 weeks showed a decline in the number 
of gadolinium-enhancing lesions on magnetic 
resonance imaging per patient; this led to a 25(OH)D 
serum concentration of 386 nmol/L (158 ng/mL) 
without causing hypercalcemia, hypercalciuria, or other 
complication.13
Ongoing, Randomized control trials are assessing 
vitamin D supplementation for the treatment and 
prevention of MS.14
RATIONALE:
The rationale of study is that the studies on the subject 
under consideration are scarce in Pakistan and 
secondly most of the studies done on retrospective 
data. Since VIT D deficiency is related to poor 
treatment results in patients with MS, this study by 
determining the frequency was lead to realization for 
early detection and timely intervention ultimately 
leading to improved morbidity rates.
OBJECTIVE
To determine the frequency of vitamin D deficiency in 
Multiple sclerosis patients present at neurology ward of 
a tertiary care hospital in Larkana.
OPERATIONAL DEFINITION
MULTIPLE SCLEROSIS:
Was defined as isolated limb weakness of power<2/5 
on MRC score with the increased tone of > 2 scores 
determined by Modified Ashworth Scale on clinical 
examination > 3 months (Appendix I and II respectively 
) and according to the 2010 McDonald diagnostic 
criteria of MS (Appendix ΙΙΙ)
VITAMIN D DEFICIENCY:
Patients were labeled Vitamin D deficient if less than 
25 nmol/l at the time of presentation.
MATERIAL AND METHOD
Study Design: Cross-sectional study
Setting:  This study was conducted at the Neurology 
Ward Chandka Medical College Hospital, Larkana.
Duration of Study: Six months March 2016 to August 
2016
Sample Size: Taking the prevalence of VIT D 
deficiency as 17%4, confidence interval at 95% and 
margin of error at 8% and putting this information in Epi 
Info 7, the sample size calculated is 85.
Sampling Technique: Non - Probability consecutive 
sampling
Inclusion Criteria:
1.  Between the ages of 18 and 60 years, 
2.  Both genders
3.  Diagnosis of MS as per operational definition  for 
     > 3 months
4.  Give written informed consent prior to any
     testing   under this protocol, including screening
     tests  and evaluations that are not considered part
     of the subject's routine care. 
5.  Sun exposure for at least 30minutes  thrice per
     week
Exclusion Criteria:
1.  Patients that have other co-morbidities like 
     heart failure determined by echo as EF>25
     renal disease   determined by serum Cr > 3mg/dl)
2. Endocrine disorders like  hyperparathyroidism 
determined by blood PTH levels > 10 ng/dl
3.  Any patient on long-term steroid treatment for
      less  than 3 months. determined by
     physician  prescription slip 
4.  Patients already on vitamin D therapy for more
     than 3   months. Doctor’s prescription as evidence.
     
Data collection procedure:
The permission for the data collection was sought from 
the Ethical review committee of the hospital, the study 
was conducted in the department of Neurology, 
department, Chandka Medical College, Larkana. After 
taking the informed written consent from the patients. 
Diagnosed cases of Multiple sclerosis was enrolled in 
the study after fulfilling inclusion/exclusion criteria. The 
researcher was collect data on a prescribed 
questionnaire regarding demographic variables like 
name, age, gender, duration of sun exposure & 
duration of disease. Blood Sample for a vitamin D level 
blood sample of these patients was drawn on the same 
day and sent to a laboratory for vitamin D level in the 
pathological lab of CMCH. Blood Vitamin D levels in this 
study was measured by radioimmunoassay. The test 
was done free of cost at CMCH, Larkana lab and the 
results of these tests were collected on reporting date 
and was entered on the Performa by researcher herself.
Data analysis procedure:
Data was analyzed on a computer using SPSS software 
version 21. Mean and SD was calculated for age, 
duration of disease, duration of sun exposure and 
Vitamin D levels. Frequency and percentages were 
calculated for gender, age group, marital status, and 
employment status and outcome variable i-e vitamin D 
deficiency. Effect variable  like age, gender, marital 
status, and employment status, duration of sun 
exposure and duration of disease were stratified to see 
the effects of these on the outcome variable. Applying 
chi-square test with p value <0.05 taken as significant.
Ethical consideration:
Permission for data collection was taken from the head 
of the department of the ward. Written informed 
consent was obtained from patients while ensuring that 
the data was kept confidential. Patients were 
thoroughly informed about the objectives and methods 
of the study.
RESULTS
A total of 85 patients were enrolled in this study during 
study period. The mean age of enrolled participants 
was 43.6±11 years. Majority of patients were less 
than 45 years accounting for 43 (50.6%) cases. Of 85 
enrolled participants, 36 (42.4%) were male and 49 
(57.6%) were female, the mean duration of disease 
was 6.2±1.4 months, 70 (82.4%) participants were 
married and 15 (17.6%) were unmarried , 49 (57.6%) 
were employed, 43 (50.6%) were exposed to the sun 
for < 40 minutes a day (Graph 1). 
Outcome of study
The frequency of vitamin D deficiency among patients 
with multiple sclerosis was 17 (20%) cases (Graph 2)
Stratified analysis:
Stratified analysis of frequency of vitamin D deficiency 
among patients with multiple sclerosis by age, gender, 
duration of disease, duration of sun exposure, marital 
status and employment status is summarized in tables 
1-6. 
Stratified analysis by age:
Of patients <45 years of age, 9 (20.9%) had vitamin D 
deficiency compared to 8 (19%) cases among patients 
of age >= 45 years (p-0.522).
Stratified analysis by gender:
Of male patients, 3 (8.3%) had vitamin D deficiency 
compared to 14 (28.6%) cases among female patients 
(p-0.019).
Stratified analysis by duration of disease: Of 
patients with duration of disease of <6 months of age, 
8 (14.8%) had vitamin D deficiency compared to 9 
(29%) cases among patients of with duration of 
disease >= 6 months (p-0.099).
Stratified analysis by duration of exposure to the 
sun: Of patients with duration of sun exposure <40 
minutes, 11 (25.6%) had vitamin D deficiency 
compared to 6 (14.3%) cases among patients of with 
duration exposure to the sun >= 40 minutes 
(p-0.151).
Stratified analysis by marital status:
Of married patients, 15 (21.4%) had vitamin D 
deficiency compared to 2 (13.3%) cases among 
unmarried patients (p-0.378).
Stratified analysis by employment status:
Of employed patients, 14 (28.6%) had vitamin D 
deficiency compared to 3 (8.3%) cases among 
unemployed patients (p-0.019).
Graph 1:




FREQUENCY OF VITAMIN D DEFICIENCY IN 
PATIENTS WITH MULTIPLE SCLEROSIS
(n=143)
Table 1: STRATIFIED ANALYSIS OF FREQUENCY OF 
VITAMIN D DEFICIENCY IN PATIENTS WITH 
MULTIPLE SCLEROSIS BY AGE
Table 2:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 




STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF 
DISEASE
Table 4:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY DURATION OF SUN EXPOSURE as 
Table 5:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY MARITAL STATUS
Table 6:
STRATIFIED ANALYSIS OF FREQUENCY OF VITAMIN 
D DEFICIENCY IN PATIENTS WITH MULTIPLE 
SCLEROSIS BY EMPLOYMENT STATUS
DISCUSSION
Hypovitaminosis D is currently one of the most studied 
environmental risk factors for multiple sclerosis (MS) 
and is potentially the most promising in terms of new 
clinical implications. The putative protective role of 
vitamin D in MS is based on a wide-ranging series of 
arguments. The first group of arguments exists outside 
of, or indeed before, the disease, including 
physiological, metabolic, experimental and 
immunological factors, in addition to which there are 
epidemiological data on the effects of latitude, past 
exposure to sunlight and serum vitamin D levels on the 
risk of MS in the general population. The second group 
of arguments stems from data on MS patients derived 
from biological and therapeutic studies.
Diseases that affect central nervous system myelin can 
be categorized as demyelinating (acquired, usually 
inflammatory) and dysmyelinating (abnormal formation 
of myelin, usually due to a genetic disease). The most 
common autoimmune inflammatory demyelinating 
disease of the central nervous system is multiple 
sclerosis (MS).
Several studies have shown that vitamin D levels are 
lower in MS patients than in controls.15-20 In this 
study, the frequency of vitamin D deficiency among 
patients with multiple sclerosis was 17 (20%). A recent 
study24 showed that in clinically isolated syndrome 
patients (namely, those suffering a single demyelinating 
attack that is compatible with MS), vitamin D deficiency 
was a predictor of developing clinically definite MS. The 
association of disease activity with vitamin D levels in 
MS patients has been evaluated in multiple studies 
that demonstrated a lower MS relapse rate in patients 
with higher levels of vitamin D. Additionally, low levels of 
vitamin D appear to be associated with high levels of 
disability as measured by the Expanded Disability 
Status Scale (EDSS). The EDSS is a commonly used 
index of clinical disability in MS, with scores ranging 
from 0 (corresponding to a normal examination and 
function) to 10 (for death due to MS). Two recent 
studies conducted in 2014 support this 
association.21, 22 In the first study, 181 patients were 
prospectively followed, and EDSS scores were 
correlated with plasma vitamin D levels. Patients with 
vitamin D levels >50-nmol/L were 2.78 times more 
likely to have an EDSS <4 (p=0.0011).25  The 
second study26 was originally designed to evaluate the 
impact of early versus delayed interferon beta-1b 
treatment in patients with clinically isolated syndrome. 
Serum 25(OH)D concentrations were measured at 
baseline and at 6, 12, and 24 months. Patients were 
followed for 5 years with clinical assessments and MRI. 
A 50-nmol/L increase in average serum 25(OH)D levels 
within the first 12 months predicted a 57% lower rate 
of new active lesions (p<0.001), a 57% lower relapse 
rate (p=0.03), and a 25% lower yearly increase in T2 
lesion volume (p<0.001) from months 12 to 60. 
Levels ≥50 nmol/L at following periods of up to 12 
months predicted lower EDSS scores (p=0.004) 
during the subsequent 4 years.26 
Observational studies correlating vitamin D levels to MS 
severity cannot prove that increased sun exposure 
alleviates the symptoms of MS, especially given that 
severely disabled patients with MS receive less sun 
exposure, which can cause vitamin D deficiency. Even 
MS patients who are fully mobile are theoretically more 
susceptible to vitamin D deficiency because they avoid 
sun exposure, worsening their symptoms.23
CONCLUSION
It is concluded from this study that the frequency of 
vitamin D deficiency among patients with multiple 
sclerosis was 20%. The frequency of vitamin D 
deficiency among male was 8.3% compared to female 
patients. Of employed patients, 14 (28.6%) had 
vitamin D deficiency compared to 3 (8.3%) cases 
among unemployed patients.
y ophthalmoplegia and areflexia while 4 patients (28%) 
presented with overlap syndrome having generalized 
weakness. In comparison to other study which showed 
that half of the patients with MFS eventually 
experienced profound weakness (overlap syndrome) 
[15].
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